In yesterday’s Wall Street session, Kymera Therapeutics Inc. (NASDAQ:KYMR) shares traded at $33.58, up 12.31% from the previous session.
As of this writing, 18 analysts cover Kymera Therapeutics Inc. (NASDAQ:KYMR). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $93.00 and a low of $31.00, we find $53.50. Given the previous closing price of $29.90, this indicates a potential upside of 78.93 percent. KYMR stock price is now 19.65% away from the 50-day moving average and 29.84% away from the 200-day moving average. The market capitalization of the company currently stands at $1.77B.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
There are 6 analysts who have given it a hold rating, whereas 12 have given it a buy rating. Brokers who have rated the stock have averaged $55.63 as their price target over the next twelve months.
With the price target reduced from $47 to $32, Credit Suisse Downgraded its rating from Outperform to Neutral for Kymera Therapeutics Inc. (NASDAQ: KYMR). , while ‘Jefferies’ rates the stock as ‘Buy’.
In other news, Booth Bruce, Director sold 3,278 shares of the company’s stock on Dec 15. The stock was sold for $98,340 at an average price of $30.00. Upon completion of the transaction, the Director now directly owns 917,811 shares in the company, valued at $30.82 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 15, 10% Owner Atlas Venture Fund X, L.P. sold 717 shares of the business’s stock. A total of $21,510 was realized by selling the stock at an average price of $30.00. This leaves the insider owning 917,811 shares of the company worth $30.82 million. Insiders disposed of 1,017,436 shares of company stock worth roughly $34.17 million over the past 1 year. A total of 11.00% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in KYMR stock. A new stake in Kymera Therapeutics Inc. shares was purchased by T. ROWE PRICE INVESTMENT MANAGEMENT, INC. during the first quarter worth $67,043,000. ECOR1 CAPITAL, LLC invested $26,733,000 in shares of KYMR during the first quarter. In the first quarter, AQUILO CAPITAL MANAGEMENT, LLC acquired a new stake in Kymera Therapeutics Inc. valued at approximately $11,090,000. BNP PARIBAS ARBITRAGE, SNC acquired a new stake in KYMR for approximately $2,545,000. QUBE RESEARCH & TECHNOLOGIES LTD purchased a new stake in KYMR valued at around $2,397,000 in the second quarter. In total, there are 186 active investors with 98.50% ownership of the company’s stock.
Thursday morning saw Kymera Therapeutics Inc. (NASDAQ: KYMR) opened at $29.90. During the past 12 months, Kymera Therapeutics Inc. has had a low of $13.15 and a high of $53.97. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 5.40, and a quick ratio of 5.40. The fifty day moving average price for KYMR is $28.07 and a two-hundred day moving average price translates $25.86 for the stock.
The latest earnings results from Kymera Therapeutics Inc. (NASDAQ: KYMR) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.78, missing analysts’ expectations of -$0.7 by -0.08. This compares to -$0.56 EPS in the same period last year. The company reported revenue of $9.55 million for the quarter, compared to $20.34 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -53.03 percent. For the current quarter, analysts expect KYMR to generate $15.51M in revenue.
Kymera Therapeutics Inc.(KYMR) Company Profile
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
